| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.transgenebiotek.com | |
| Market Cap | 53.11 Cr. | |
| Enterprise Value(EV) | 67.73 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -0.25 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 66.45 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 1.45 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 4.84 | Calculated using Price: 7.01 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 7.58 Cr. | 75,770,000 Shares |
| FaceValue | 10 | |
| About Transgene Biotek Ltd. | ||
| Transgene Biotek Ltd (TBL) was set up in 1991, and was probably the first true Biotechnology Company in India. It is listed on the Indian Stock Exchanges and is involved in the development of several cutting edge technologies. | ||
| 1 Day |
|
-0.71% |
| 1 Week |
|
-6.15% |
| 1 Month |
|
-13.87% |
| 3 Month |
|
-32.69% |
| 6 Month |
|
+65.96% |
| 1 Year |
|
+160.97% |
| 2 Year |
|
+91.80% |
| 5 Year |
|
+52.94% |
| 10 Year |
|
+58.47% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -9.63 | -11.78 | -17.03 | -11.57 | -18.31 | -28.73 | -38 | -52.51 | -41.8 | |
| Return on Capital Employed (%) | -8.84 | -10.85 | -14.68 | -6.74 | -14.83 | -22.1 | -26.55 | -32.32 | -19.99 | |
| Return on Assets (%) | -5.45 | -6.56 | -7.77 | -3.35 | -4.84 | -6.39 | -6.45 | -6.84 | -4.15 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 191 | 174 | 59 | 52 | 44 | 33 | 22 | 17 | 11 | 11 | |
| Non Curr. Liab. | 127 | 127 | 127 | 120 | 120 | 120 | 120 | 121 | 121 | 121 | |
| Curr. Liab. | 25 | 11 | 12 | 14 | 13 | 14 | 14 | 9 | 10 | 11 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 | |
| Non Curr. Assets | 326 | 310 | 197 | 186 | 176 | 166 | 156 | 146 | 141 | 141 | |
| Curr. Assets | 18 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 344 | 313 | 198 | 187 | 177 | 167 | 157 | 147 | 142 | 142 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other Income | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 0 | 0 | 1 | 7 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Total Expenditure | -2 | -1 | -3 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | |
| PBIDT | -2 | -1 | -2 | 5 | 1 | -1 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | -1 | 0 | |
| Depreciation | -17 | -21 | -18 | -10 | -10 | -10 | -10 | -10 | -5 | -1 | |
| Taxation | -1 | ||||||||||
| Exceptional Items | |||||||||||
| PAT | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | -6 | -2 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -19 | -22 | -20 | -6 | -9 | -11 | -10 | -10 | -6 | -2 | |
| Adjusted EPS | -3 | -3 | -3 | -1 | -1 | -1 | -1 | -1 | -1 | 0 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 4 | 6 | 0 | -1 | -2 | 0 | 0 | 0 | ||
| Cash Fr. Inv. | 1 | -5 | -6 | 3 | 2 | 0 | 0 | 0 | |||
| Cash Fr. Finan. | 1 | 1 | -2 | 0 | |||||||
| Net Change | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Thu, 25 Apr 2024
COMPLIANCE CERTIFICATE AS PER CLAUSE 40(9) OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS 2015 FOR THE YEAR ENDED 31St MARCH 2024. COMPLIANCE CERTIFICATE AS PER CLAUSE 40(9) |
|||||||||||||||||||||
|
Tue, 23 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: ANKITA JAIN Designation: COMPANY SECRETARY EmailId: cs@transgenebiotek.com Name of the Chief Financial Officer: PRASAD CHOWDARY Designation: CFO EmailId: cs@transgenebiotek.com Date: 23/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Tue, 23 Apr 2024
Compliance Certificate Reg 7(3) Compliance Certificate Reg 7(3) |
| Thu, 02 May 2024 |
High Decrease in 1 Month
|
High Decrease in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
High Increase in 2 Years
|
